CTRI/2016/09/007308已完成未知
â??Exploring the utility of circulating tumor DNA in monitoring response to therapy and in aiding follow up of breast cancer patients using the neoadjuvant setting as a modelâ??
DEPARTMENT OF BIOTECHNOLOGY0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Patients just diagnosed with breast cancer and planned for NACT.
- •Patients willing to provide written informed consent to participate in the study.
- •Patients whose tumors have any receptor phenotype.
- •Patients willing to receive the usual standard treatment in NACT setting
排除标准
- •Patients with metastatic disease will not be included.
研究者
相似试验
已完成
不适用
Prospective Evaluation of Circulating Tumour DNA (ctDNA) as Molecular Monitoring Tool and Prognostic Biomarker in Resectable Pancreatic AdenocarcinomasC25Malignant neoplasm of pancreasDRKS00010992niversitätsklinikum Freiburg25
招募中
不适用
Quantification of Circulating tumor DNA to assess treatment response in metastatic prostate cancer patientsmetastatic prostate cancerNL-OMON24467Erasmus Medical Center95
撤回
不适用
A Study of the Role of Circulating Tumor DNA in Predicting the Likelihood of Organ Preservation After Clinical Complete Response to Neoadjuvant Therapy for Rectal CancerGastrointestinal MalignanciesNCT03749083Massachusetts General Hospital
招募中
不适用
Circulating tumor DNA (ctDNA) analyses as a predictive marker for cancer treatment in solid tumorsKCT0008188Chonnam National University Hospital Hwasun Hospital100
招募中
不适用
Circulating tumor DNA as a noninvasive biomarker in patients with thyroid cancerC73Malignant neoplasm of thyroid glandDRKS00022441niversitätsklinikum Freiburg75